Legal & General Group Plc grew its position in Boston Scientific Corporation (NYSE:BSX – Free Report) by 4.0% in the fourth quarter, Holdings Channel reports. The fund owned 10,876,617 shares of the medical equipment provider’s stock after acquiring an additional 419,442 shares during the quarter. Legal & General Group Plc’s holdings in Boston Scientific were worth $1,037,085,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of BSX. Egerton Capital UK LLP lifted its stake in shares of Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the last quarter. Alphinity Investment Management Pty Ltd bought a new position in shares of Boston Scientific in the 4th quarter valued at $252,918,000. Marshall Wace LLP lifted its stake in shares of Boston Scientific by 30.7% in the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares during the last quarter. Credit Agricole S A acquired a new stake in Boston Scientific in the third quarter valued at $204,812,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Boston Scientific by 28.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock valued at $816,909,000 after purchasing an additional 1,837,480 shares during the period. 89.07% of the stock is currently owned by institutional investors.
Boston Scientific Stock Performance
Shares of Boston Scientific stock opened at $57.71 on Monday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $61.97 and a two-hundred day moving average price of $80.12. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The company has a market cap of $85.77 billion, a P/E ratio of 24.15, a PEG ratio of 1.06 and a beta of 0.62.
Boston Scientific announced that its Board of Directors has authorized a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.
Key Boston Scientific News
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
- Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
- Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
- Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
- Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title
Insiders Place Their Bets
In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.
Analysts Set New Price Targets
A number of analysts recently weighed in on the company. Oppenheimer set a $90.00 price objective on Boston Scientific in a report on Thursday, April 23rd. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Jefferies Financial Group decreased their price objective on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Wells Fargo & Company decreased their price objective on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. Finally, Evercore decreased their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $92.71.
Read Our Latest Analysis on Boston Scientific
Boston Scientific Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
